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13.09.002Abstract Induced pluripotent stem cells (iPSCs) are generated by ectopic expression of deﬁned
transcription factors in somatic cells. They can undergo unlimited self-renewal and maintain the
embryonic stem cells (ESCs)-like ability to differentiate into all three germ layers. iPSCs can poten-
tially provide unlimited autologous cells for therapy and therefore hold great promise for regener-
ative medicine. Here we reviewed the recent advances in iPSC studies on disease modeling and
clinical treatment as well as challenges correlated with clinical development of iPSCs, like tumori-
genicity, immunogenicity and genomic instability.Introduction
In 2006, using Fbx15bgeo as a reporter system, Yamanaka’s
group screened a panel of genes speciﬁcally expressed in
embryonic stem cells (ESCs) and determined that four tran-
scription factors–– Oct4, Sox2, Klf4 and c-Myc–– are sufﬁcient
to reprogram mouse ﬁbroblasts into pluripotent stem cells,
which we called induced pluripotent stem cells (iPSCs) [1].
The same cocktail can also reprogram human differentiated
ﬁbroblast into iPSCs [2–5]. In 2007, Thomson’s group
identiﬁed another combination –– Oct4, Sox2, Lin28 and
Nanog –– that can induce human somatic cells to become
pluripotent [6]. Like ESCs, iPSCs can undergo unlimited self-
renewal and maintain the ability to differentiate into all three
germ layers. iPSCs can not only contribute to chimerism and
germ line transmission in mice, but also can develop into.
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jing Institute of Genomics, Chinese Afull-term iPSC mice by tetraploid complementation [1–3,7–
10], indicating the totipotency of iPSCs.
Somatic cell conversion to the iPSC state is accompanied by
epigenetic remodeling, including resetting of the chromatin
structure and methylation states of DNA and histone. The
process of cell fate switching that culminates in the iPSC phe-
notype makes this type of cell an ideal model for studying basic
biological phenomena such as development and differentia-
tion. The low efﬁciency of reprogramming and long period
of time required for reprogramming to occur complicate ef-
forts to study the mechanism of reprogramming, which has
been widely discussed and reviewed [11–14]. In this review, in-
stead of discussing the reprogramming mechanisms, we focus
on the promises and challenges of using iPSCs therapeutically.
Disease modeling
Theoretically, patient-speciﬁc iPSCs can be obtained and dif-
ferentiated into different cell types with the same genetic back-
ground as the donor patient, providing the opportunity to
study pathogenesis in vitro, so-called ‘‘modeling disease in a
dish’’. Indeed, iPSCs have already been derived from patients
with a large variety of diseases [12]. It is very challenging to
study the pathogenesis of human neurological disease, due tocademy of Sciences and Genetics Society of China. Production and hosting
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turing neurons in vitro. iPSCs are a practical means of studying
the development and function of human neurons. Spinal mus-
cular atrophy was the ﬁrst neurological disease targeted in a
human iPSC-based study of pathogenesis [15]. The patient-de-
rived iPSCs generated in the study gave rise to motor neurons
with the same genotype that is associated with selective deﬁcits,
providing the proof of concept that iPSCs can be used to mod-
el human disease [15]. In another study, iPSCs derived from
Rett syndrome patients were not only able to recapitulate
the hallmark defects associated with the disease but were also
used to test the effects of drugs in rescuing synaptic defects
[16].
Recent studies in which iPSCs have been derived from pa-
tients with Huntington-Gilford progeria syndrome (HGPS)
have shown that the smooth muscles derived from the patient
iPSCs recapitulated the premature senescence in vitro, suggest-
ing great promise for elucidating the molecular mechanisms
underlying the HGPS disease by using iPSCs [17,18]. Interest-
ingly, Liu et al. demonstrated the contribution of the LRRK2
G2019S mutation to Parkinson’s disease (PD), and for the ﬁrst
time showed that nuclear-envelope defects might be involved
in PD pathology, opening new avenues for PD diagnoses
and treatment [19]. iPSCs have also been used to model cardiac
disease. iPSCs derived from patients with long-QT syndrome
were induced to differentiate into functional cardiac myocytes
that recapitulated the electrophysiological defects characteris-
tic of the disorder [20].
Using iPSC-derived patient-speciﬁc cells to model an adult-
onset disease remains challenging, owing to the difﬁculties in-
volved in differentiating the iPSCs into an adult organ and the
complexity of pathogenesis associated with development. Kim
et al. provided the ﬁrst evidence that induction of adult-like
metabolism has a crucial role in establishing the adult-onset
disease arrhythmogenic right ventricular dysplasia (ARVD)
using patient-speciﬁc iPSCs [21].
Those preliminary studies inspired more-extensive disease
modeling studies using iPSCs. To date, dozens of disorders
affecting neurons, blood, liver, heart, pancreas, lung as well
immunological disorders and cancer were studied by using iPS-
Cs [12,22,23]. Lack of appropriate model systems is a major
block to the study of human hepatitis C virus (HCV) infection
in humans. Interestingly, it was recently reported that hepato-
cyte-like cells derived from iPSCs can support the entire life cy-
cle of HCV in humans, validating the feasibility of using iPSC
as a model system to study human HCV infection [22,24]. In
support of this idea, another recent study showed that hepatic
cells derived from pigtail macaque can also support HCV
infection [25].
Despite plenty of disease modeling using cells differentiated
from iPSCs, generation of complex three-dimensional organs
and tissues for regenerative medicine is still a major challenge.
Two inspiring studies showed that three-dimensional intestine
and liver can be derived from iPSCs [26,27], providing
proof-of-concept that iPSCs can be used to generate functional
organs in vitro for regenerative medicine.
iPSCs for therapy
The ﬁrst proof-of-principle experiment involving the use of
iPSCs to cure disease was performed by the Jaenisch lab, usinga humanized sickle cell anemia mouse model [28]. Hanna et al.
ﬁrst derived the mouse iPSCs, corrected the sickle hemoglobin
allele by gene-speciﬁc targeting, differentiated the iPSCs into
hematopoietic progenitors, and then transplanted these cor-
rected progenitors into the mice. This strategy successfully res-
cued the phenotype of the blood cells [28]. By transplanting
human iPSC-derived multipotent cardiovascular progenitor
cells into mouse, Lu et al demonstrated that the transplanted
cardiovascular progenitor cells can migrate, proliferate and
differentiate in situ into cardiomyocytes, smooth muscle cells
and endothelial cells to reconstruct the damaged heart [29].
The clinical development of human iPSCs for therapy is still
in its preliminary stage. There are two encouraging clinical tri-
als using human ESC (hESC)-derived cells for therapy in the
USA that have been approved by the FDA. Geron performed
the ﬁrst FDA-approved clinical trials using hESC-derived cells
to treat spinal cord injury (www.clinicaltrials.gov). Another,
more-encouraging trial was performed by Advanced Cell
Technology (ACT), using hESC-derived retinal pigment epi-
thelial (RPE) cells to treat macular degeneration (MD).
Although no signiﬁcant vision improvement has been observed
four months after transplantation, structural evidence con-
ﬁrms that cells have attached and continued to persist in the
treated patients. Most importantly, no hyperproliferation,
abnormal growth, or immune-mediated transplant rejection
was observed in these transplanted patients, and no patients
lost their vision during the ﬁrst four months [25,30]. Subse-
quent clinical observations are expected. Meanwhile, a preli-
minary clinical trial for transplantation of iPSC-derived RPE
cells was performed by Masayo Takahashi in Japan, as re-
ported in the ISSCR 2012 Annual Meeting. Publication of
those clinical data is eagerly expected.
Tumorigenicity
The boosting of patient-speciﬁc iPSC derivation and iPSC-
based disease modeling underscores the great potential use of
this technology in regenerative medicine. However, to translate
the iPSC technology to therapy quickly, extensive preclinical
experiments are required to evaluate the safety and effective-
ness of this new type of therapy.
The ﬁrst generation of iPSCs were obtained by overexpress-
ing the deﬁned transcription factors, using retrovirus or lenti-
virus [1,2,5,6]. Integration of the viral genome into that of the
host poses a serious cancer risk [7,31]. iPSCs were subsequently
generated without viral integration by using piggyBac transpo-
sition [32,33]. Soon after, adenovirus or plasmid or episomal
vector transfection was successfully used to reprogram ﬁbro-
blast into iPSCs, both in mouse and human [34–40]. Moreover,
two recent studies showed that both mouse and human iPSCs
can be obtained by directly delivering reprogramming factor
proteins into target cells without any DNA manipulation
[41,42]. All of the aforementioned methods used for repro-
gramming can be applied to generate iPSCs without exogenous
DNA integration into the host genome. Remarkably, tumors
were not observed in mice derived from integration-free iPSCs
up to 20 weeks of age [35]. Recently, mouse iPSCs were gener-
ated by adding only seven small molecule compounds into the
cell culture, suggesting the possibility of generating human
iPSCs for clinical application without tedious genetic manipu-
lations [43]. This study indicates that cell fate decisions can be
296 Genomics Proteomics Bioinformatics 11 (2013) 294–298dictated by manipulating intrinsic signal pathways, and repre-
sents an innovative breakthrough in the understanding of
reprogramming mechanisms.
The cancer risks raised by virus or reprogramming factor
integration into the genome could be averted by the use of inte-
gration-free reprogramming technologies. However, whether
reprogramming itself can lead to tumorigenesis is still unknown.
The iPSC reprogramming factors have clearly demonstrated
oncogenicity. Oct4 was shown to dictate the oncogenic poten-
tial of ESCs in a dose–dependent way. Overexpression of
Oct4 enhances the malignant potential of ESC-derived tumors,
while inactivation decreases malignant potential [44–46]. Sox2
is a lineage-survival oncogene in lung and esophageal squa-
mous cell carcinomas [47]. Klf4 functions as a tumor suppres-
sor gene and oncogene in a context-dependent manner [48].
c-Myc is an oncogene as well [49]. Nanog expression has been
detected in various tumors and is thought to be an oncogene
[50,51]. Recent studies showed that Nanog can promote breast
cancer tumorigenesis and metastasis [52]. The overexpression
of oncogenic genes can potentially make cells grow out of con-
trol and cancerous. The oncogenicity of reprogramming factors
can transform some of cells during reprogramming [53]. During
reprogramming, some ES-like colonies failed to expand when
the original ‘‘iPS’’ colonies were picked up, other ES-like colo-
nies can be expanded but lack pluritpotency-deﬁned partially
reprogrammed iPSCs [53]. Whether the bulk transfection of
oncogenic reprogramming factors into somatic cells can cause
abnormality in iPSCs is still under investigation.
Immunogenicity
Although it is widely assumed that iPSC-derived autologous
cells are immune privileged, the immunogenicity of cells differ-
entiated from iPSCs is not extensively studied. Recently, we
ﬁrst showed that iPSC derivatives can elicit immune rejection
response when transplanted to the syngeneic mice by using a
teratoma model [40]. Although two following-up studies
claimed either ‘‘negligible’’ or ‘‘lack of’’ immunogenicity of
iPSC derivatives, they both support that some certain tissues
but not all tissues differentiated from iPSCs are immunogenic.
Abe group clearly showed that the cardiomyocytes differenti-
ated from iPSCs can elicit immune rejection responses (please
refer to Sup Fig. 13) [54]. Recent report by Guha et al. clearly
showed the immunogenicity differences between ESC- and
iPSC- derived endoderm cells [55].
It should be noted that (1) only certain but not all tissues de-
rived from iPSCs can elicit immune rejection response; (2) the
rejection intensity induced by ESC-derived allografts differs
from that induced by iPSC-derived autografts, due to the fact
that MHC-I molecules are expressed in all allogeneic ESC-de-
rived cells and only certain syngeneic iPSC derivatives can ex-
press minor antigens; (3) if a speciﬁc autologous cell type
derived from iPSCs is immunogenic, it is capable of eliciting
serious minor antigen-induced rejection of the cells. In general,
we can still take easier advantage of iPSCs for therapy than allo-
geneic ESC lines even when immunologic issues are considered.
Genomic instability
Many studies have identiﬁed chromosomal abnormalities in
iPSCs, indicating that reprogramming itself can induce geneticinstability. Recently, sub-karyotype abnormalities were de-
ﬁned in multiple iPSC lines by using Array Comparative
Genomic Hybridization (aCGH) [56]. Comparative genomic
hybridization analysis of iPSCs revealed the presence of geno-
mic deletions and ampliﬁcations, suggesting oncogene-induced
DNA replication stress during reprogramming [57]. High-reso-
lution single nucleotide polymorphism (SNP) analysis revealed
a higher frequency of subchromosomal copy number varia-
tions (CNVs) in human iPSCs compared to somatic cells
[58]. Similarly, another study showed that early-passage hu-
man iPSCs harbor signiﬁcantly more chromosomal CNVs
than do intermediate human iPSCs, ﬁbroblasts or human
ESCs. Interestingly, in that study, iPSCs with CNVs were rap-
idly disappeared in the iPSC pool during expansion [59]. By
using deep sequencing, a recent study detected somatic coding
mutations in human iPSCs, suggesting that human iPSCs ac-
quire not only epigenetic but also genetic modiﬁcations [60].
The tumor suppressor p53 functions as the guardian of the
genome, as it is involved inDNAdamage response, cell cycle ar-
rest, senescence and apoptosis [61–63]. Recent studies clearly
showed that p53 is a barrier to reprogramming [64–69]. Inhibi-
tion of p53 activity can enhance reprogramming efﬁciency.
However,whether inactivation of p53 is required for reprogram-
ming and whether p53 inactivation directly contributes to geno-
mic instability in iPSCs are questions still under investigation.
Perspective
Although signiﬁcant progress has been made in understanding
tumorigenicity, immunogenicity and genomic instability in
iPSCs, the relationship among these abnormalities and how
to overcome the associated hurdles for clinical development
of iPSCs are still undergoing study. Meanwhile, encouraging
progress in the development of integration-free reprogram-
ming approaches, disease modeling, and preclinical trials has
signiﬁcantly enhanced the prospects of advancing iPSC tech-
nology from bench to bedside.
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